Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore

Abstract

BackgroundDengue illness causes 50–100 million infections worldwide and threatens 2.5 billion people in the tropical and subtropical regions. Little is known about the disease burden and economic impact of dengue in higher resourced countries or the cost-effectiveness of potential dengue vaccines in such settings.Methods and FindingsWe estimate the direct and indirect costs of dengue from hospitalized and ambulatory cases in Singapore. We consider inter alia the impacts of dengue on the economy using the human-capital and the friction cost methods. Disease burden was estimated using disability-adjusted life years (DALYs) and the cost-effectiveness of a potential vaccine program was evaluated. The average economic impact of dengue illness in Singapore from 2000 to 2009 in constant 2010 US$ ranged between $0.85 billion and $1.15 billion, of which control costs constitute 42%–59%. Using empirically derived disability weights, we estimated an annual average disease burden of 9–14 DALYs per 100 000 habitants, making it comparable to diseases such as hepatitis B or syphilis. The proportion of symptomatic dengue cases detected by the national surveillance system was estimated to be low, and to decrease with age. Under population projections by the United Nations, the price per dose threshold for which vaccines stop being more cost-effective than the current vector control program ranged from $50 for mass vaccination requiring 3 doses and only conferring 10 years of immunity to $300 for vaccination requiring 2 doses and conferring lifetime immunity. The thresholds for these vaccine programs to not be cost-effective for Singapore were $100 and $500 per dose respectively.ConclusionsDengue illness presents a serious economic and disease burden in Singapore. Dengue vaccines are expected to be cost-effective if reasonably low prices are adopted and will help to reduce the economic and disease burden of dengue in Singapore substantially.

Disease burden of enterovirus 71 in rural central China: A community-based survey

“…35 We used the human capital approach to estimate these indirect costs. 36,37 Because most subjects were less than 6 years old, the cost of school days lost was negligible.…”

Dengue myocarditis in Singapore: two case reports

“…The dengue incidence rate was 98.1/100,000 population in 2010, with a case-fatality ratio of 0.08 % [1]. Although the incidence rate was not the highest in the Asia-Pacific region, the disease had high economic impact [2]. It was estimated that the average economic impact of dengue illness in Singapore over one 10-year period from 2000 to 2009 was between US$ 0.85 billion and US$ 1.15 billion [2].…”

Pharmacoeconomic Evaluation for Dengue Vaccine Pricing for Malaysia: Towards Affordability, Cost Effectiveness and Sustainability

“…Another recent study in Singapore concluded that a dengue vaccine involving three doses and conferring ten years of immunity would be cost-effective at a price threshold of USD 95 per dose, given Singapore GDP per capita of about USD 55,000. However, the authors admitted several limitations in the estimation of the economic and disease burdens [11]. The low efficacy and theoretical increase in risk due to vaccineinduced ADE have not been incorporated in their current pricing model.…”

“…The vaccine coverage fc required to bring the basic reproduction number R0 to below 1 with a vaccine efficacy α is given as [11]:…”